

PUBBLICAZIONI SCIENTIFICHE 2015 DEL CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO

	TITOLO ARTICOLO	AUTORI	RIVISTA	ANNO	VOLUME	ISSUE	PAGINE	DOI	TIPO DI PUBBLICAZIONE
1	A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.	Rossio R , Lotta LA, Pontiggia S , Borsa NG, Garagiola I , Ardissino G, Mikovic D, Cugno M , Peyvandi F	Haematologica	2015	100	3	e87-9	doi: 10.3324/haematol.2014.111062.	Letter
2	Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient.	Ferrari B , Cairo A , Pontiggia S , Mancini I , Masini L, Peyvandi F	Journal of Clinical Apheresis	2015	30	4	252-6	doi: 10.1002/jca.21366.	Article
3	Rare Bleeding Disorders: diagnosis and treatment	Palla R , Peyvandi F , Shapiro AD	Blood Journal	2015	125	13	52-61	doi: 10.1182/blood-2014-08-532820.	Review
4	Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency.	Asselta R, Platé M, Robusto M, Borhany M, Guella I, Soldà G, Afrasiabi A, Menegatti M , Shamsi T, Peyvandi F , Duga S.	Thrombosis and Haemostasis	2015	113	3	567-76	doi: 10.1160/TH14-07-0629.	Article
5	Factor VIII products in haemophilia A: one size fits all?	Mannucci PM, Garagiola I .	Thrombosis and Haemostasis	2015	113	5	911-4	doi: 10.1160/TH15-04-0273.	Editorial focus (with data)
6	Treatment of Hemophilia in the Near Future.	Peyvandi F , Garagiola I .	Seminars in Thrombosis and Hemostasis	2015	41	8	838-48	doi: 10.1055/s-0034-1543998	Review
7	Long-term prophylaxis in severe factor VII deficiency	Siboni SM , Biguzzi E , Mistretta C , Garagiola I , Peyvandi F	Haemophilia	2015	21	6	812-9	doi: 10.1111/hae.12702	Article
8	Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome	Passamonti SM , Di Berardino F, Bucciarelli P , Berto V, Artoni A , Gianniello F , Ambrosetti U, Cesarani A, Pappalardo E , Martinelli I	Thrombosis Research	2015	135	3	508-12	doi: 10.1016/j.thromres.2015.01.001.	Article
9	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels	Bucciarelli P , Siboni SM , Stufano F , Biguzzi E , Canciani MT , Baronciani L , Pagliari MT , La Marca S , Mistretta C , Rosendaal FR, Peyvandi F	Journal of Thrombosis and Haemostasis	2015	13	2	228-36	doi: 10.1111/jth.12799.	Article
10	Management of pregnancy in type 2B von Willebrand disease: case report and literature review	Biguzzi E , Siboni SM , Ossola MW, Zaina B, Migliorini AC, Peyvandi F .	Haemophilia	2015	21	1	e98-103	doi: 10.1111/hae.12580	Letter
11	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.	Pengo V, Testa S, Martinelli I , Ghirarduzzi A, Legnani C, Gresele P, Passamonti SM , Bison E, Denas G, Jose SP, Banzato A, Ruffatti A.	Thrombosis Research	2015	135	1	46-9	doi: 10.1016/j.thromres.2014.10.013.	Article
12	Comparison between clinical indicators of transmembrane oxygenator thrombosis and multidetector computed tomographic analysis.	Panigada M, L'Acqua C, Passamonti SM , Mietto C, Protti A, Riva R, Gattinoni L.	Journal of Critical Care	2015	30	2	441.e7-13	doi: 10.1016/j.jcrc.2014.12.005.	Article

13	The "Pregnancy Health-care Program" for the prevention of venous thromboembolism in pregnancy.	Testa S, Passamonti SM , Paoletti O, Bucciarelli P , Ronca E, Riccardi A, Rigolli A, Zimmermann A, Martinelli I .	Internal and Emergency Medicine	2015	10	2	129-34	doi: 10.1007/s11739-014-1111-6.	Article
14	How the Direct Oral Anticoagulant Apixaban Affects Hemostatic Parameters. Results of a Multicenter Multiplatform Study.	Tripodi A , Padovan L , Testa S, Legnani C, Chantarangkul V , Scalambrino E , Ludovici E, Bassi L, Peyvandi F .	Clinical Chemistry and Laboratory Medicine	2015	53	2	265-73	doi: 10.1515/cclm-2014-0531.	Article
15	Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe haemophiliacs: comment.	Tripodi A , Chantarangkul V , Santagostino E .	Journal of Thrombosis and Haemostasis	2015	13	1	163-4	doi: 10.1111/jth.12769.	Letter (no data)
16	Periprocedural management of rivaroxaban-treated patients.	Imberti D, Ambrosoli A, Cimminiello C, Compagnone C, Fanelli A, Tripodi A , Ottani F	Expert Opinion on Pharmacotherapy	2015	16	5	685-91	doi: 10.1517/14656566.2015.1013939.	Review
17	International survey on D-dimer test reporting. A call for standardization.	Lippi G, Tripodi A , Simundic AM, Favaloro EJ.	Seminars in Thrombosis and Hemostasis	2015	41	3	287-93	doi: 10.1055/s-0035-1549092.	Article
18	Liver Disease and Hemostatic (Dys)function	Tripodi A	Seminars in Thrombosis and Hemostasis	2015	41	5	462-7	doi: 10.1055/s-0035-1550440	Review
19	Hemostasis abnormalities in cirrhosis	Tripodi A	Current Opinion in Hematology	2015	22	5	406-12	doi: 10.1097/MOH.0000000000000164	Review
20	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation.	Antonucci E, Poli D, Tosoletto A, Pengo V, Tripodi A , Magrini N, Marongiu F, Palareti G; START-Register .	PLoS One	2015	10	5	e0124719	doi: 10.1371/journal.pone.0124719.	Article (multicenter study)
21	How the direct oral anticoagulant apixaban affects thrombin generation parameters.	Tripodi A , Padovan L , Chantarangkul V , Scalambrino E , Testa S, Peyvandi F .	Thrombosis Research	2015	135	6	1186-90	doi: 10.1016/j.thromres.2015.03.032.	Article
22	Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis.	Bitto N, Salerno F, Tripodi A , La Mura V.	Journal of Hepatology	2015	63	1	277-8	doi: 10.1016/j.jhep.2015.02.027.	Letter
23	Mediterranean spotted fever and hearing impairment: a rare complication.	Rossio R , Conalbi V, Castagna V, Recalcati S, Torri A , Coen M, Cassulini LR, Peyvandi F .	International Journal of Infectious Diseases	2015	35	-	34-36	doi: 10.1016/j.ijid.2015.04.005.	Article
24	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia	Rossio R , Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F , Biganzoli EM, Nobili A, Mannucci PM, REPOSI Investigators (Ferrari F)	European Journal of Internal Medicine	2015	26	5	330-7	doi: 10.1016/j.ejim.2015.04.002.	Article (multicenter study)

25	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study	Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; on behalf of REPOSI Investigators (Peyvandi F, Rossio R, Moreo G, Ferrari F).	European Journal of Internal Medicine	2015	26	4	243-9	doi: 10.1016/j.ejim.2015.02.018.	Article (multicenter study)
26	Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.	Fischer K, Lassila R, Peyvandi F , Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; on behalf of the EUHASS participants (Mancuso ME)	Thrombosis and Haemostasis	2015	113	5	968-75	doi: 10.1160/TH14-10-0826	Article (multicenter study)
27	Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.	Marcucci M, Mancuso ME , Santagostino E , Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U.	Thrombosis and Haemostasis	2015	113	5	958-67	doi: 10.1160/TH14-07-0621.	Article
28	Design of Clinical Trials for New Products in Hemophilia: Communication from the SSC of the ISTH.	Dimichele DM, Lacroix-Desmazes S, Peyvandi F , Srivastava A, Rosendaal FR; The Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders	Journal of Thrombosis and Haemostasis	2015	13	5	876-9	doi: 10.1111/jth.12882	Article
29	Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function	Pastorelli L, Dozio E, Pisani LF, Boscolo-Anzoletti M , Vianello E, Munizio N, Spina L, Tontini GE, Peyvandi F , Corsi Romanelli MM, Vecchi M	Gastroenterology Research and Practice	2015	Article ID 189341		10 pages	doi: 10.1155/2015/189341.	Article
30	Platelet mitochondrial dysfunction in critically ill patients: comparison between sepsis and cardiogenic shock	Protti A, Fortunato F, Artoni A , Lecchi A , Motta G , Mistraretti G, Novembrino C, Comi GP, Gattinoni L.	Critical Care	2015	19	1	39	doi: 10.1186/s13054-015-0762-7.	Article
31	Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis.	Lecchi A , Razzari C, Paoletta S, Dupuis A, Nakamura L, Ohlmann P, Gachet C, Jacobson KA, Zieger B, Cattaneo M.	Blood Journal	2015	125	6	1006-13	doi: 10.1182/blood-2013-07-517896.	Article
32	Plasma ADAMTS13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.	Maino A , Siegerink B, Lotta LA, Crawley JTB, le Cessie S, Leebeek FWG, Lane Da, Lowe GDO, Peyvandi F , Rosendaal FR	Journal of Thrombosis and Haemostasis	2015	13	8	1396-1404	doi: 10.1111/jth.13032.	Article

33	Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up	Corsini I, Menegatti M, Cairo A , Dani C	Blood coagulation & fibrinolysis	2015	26	6	679-81	doi: 10.1097/MBC.0000000000000305	Article
34	Activation of Blood Coagulation in two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk	Cugno M , Tedeschi A, Borghi A, Bucciarelli P , Asero R, Venegoni L, Griffini S, Grovetti E , Berti E, Marzano AV	Plos One	2015	10	6	e0129456	doi: 10.1371/journal.pone.0129456. eCollection 2015	Article
35	Introduction and overview.	Mannucci PM, Peyvandi F	Blood Reviews	2015	29	Suppl 1	S1-3	doi: 10.1016/S0268-960X(15)30001-1.	Commentary
36	Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on fibrinogen γ -module.	Asselta R, Robusto M, Braidotti P, Peyvandi F , Nastasio S, D'Antiga L, Perisic VN, Maggiore G, Caccia S, Duga S.	Journal of Thrombosis and Haemostasis	2015	13	8	1459-67	doi: 10.1111/jth.13021.	Article
37	Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation.	Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F , Duga S.	Thrombosis Research	2015	136	1	168-74	doi: 10.1016/j.thromres.2015.05.007.	Article
38	Genetic studies of body mass index yield new insights for obesity biology.	Locke AE, et al COLLABORATORS (Peyvandi F.)	Nature	2015	518	7538	197-206	doi: 10.1038/nature14177.	Article (multicenter study)
39	Research in haemophilia B--approaching the request for high evidence levels in a rare disease.	Berger K, Schopohl D, Hilger A, Behr Gross ME, Giangrande P, Peyvandi F , Seitz R, Schramm W.	Haemophilia	2015	21	1	4-20	doi: 10.1111/hae.12603.	Review
40	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy.	Marengoni A, Nobili A, Corli O, Djade CD, Bertoni D, Tettamanti M, Pasina L, Corrao S, Salerno F, Marcucci M, Mannucci PM; REPOSI investigators (Peyvandi F, Moreo G, Ferrari B)	Internal and Emergency Medicine	2015	10	3	305-13	doi: 10.1007/s11739-014-1131-2.	Article (multicenter study)
41	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.	Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, Moro A, Savi F, Castelli R , Brambilla C, Bianchi P, Primignani M, Cortelezzi A, Bosari S.	Leukemia Research	2015	39	5	525-9	doi: 10.1016/j.leukres.2015.03.009.	Article
42	Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization.	Castelli R, Cugno M , Gianelli U, Pancrazzi A, Vannucchi AM.	Pathology Research and Practice	2015	211	4	341-3	doi: 10.1016/j.prp.2014.10.004.	Article
43	Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment.	Cugno M , Tedeschi F, Ardissino G.	Journal of Thrombosis and Haemostasis	2015	13	3	485-6	doi: 10.1111/jth.12764.	Letter (no data)

44	Inhibitor development and mortality in non-severe hemophilia A.	Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group (Santagostino E, Mancuso ME)	Journal of Thrombosis and Haemostasis	2015	13	7	1217-25	doi: 10.1111/jth.12990	Article (multicenter study)
45	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.	van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME , Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K, Insight Study Group FT	Thrombosis and Haemostasis	2015	114	1	46-55	dx.doi.org/10.1160/TH14-11-0940	Article (multicenter study)
46	Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study	Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, Gagliano F, Zanon E, Mancuso ME , Valdré L, Mameli L, Amoresano S, Mathew P, Coppola A; POTTER Study Group (Santagostino E)	Thrombosis and Haemostasis	2015	114	1	35-45	dx.doi.org/10.1160/TH14-05-0407	Article (multicenter study)
47	Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.	Fogarty PF, Mancuso ME , Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A; the Global Emerging HEmophilia Panel (GEHEP) .	Haemophilia	2015	21	5	589-97	doi: 10.1111/hae.12652.	Article (multicenter study)
48	Factors influencing illness representations and perceived adherence in haemophilic patients: a pilot study	Lamiani G, Strada I, Mancuso ME , Coppola A, Vegni E, Moja EA; the Pro-Adherence Study Group .	Haemophilia	2015	21	5	598-604	doi: 10.1111/hae.12654.	Article (multicenter study)
49	A Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients.	Riva S, Cutica I, Krampe C, Reinecke LF, Russell-Edu W, Santoro C, Rocino A, Santagostino E , Rusconi V, Pravettoni G.	Frontiers in Human Neuroscience	2015	9	313		doi: 10.3389/fnhum.2015.00313	Article
50	Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.	Santagostino E , Escobar M, Ozelo M, Solimeno L, Arkhammar P, Lee HY, Rosu G, Giangrande P.	Blood Reviews	2015	29	Suppl 1	S9-S18	doi: 10.1016/S0268-960X(15)30003-5.	Article

51	Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™ 2 extension trial.	Ozelo M, Misgav M, Abdul Karim F, Lentz SR, Martin-Salces M, Matytsina I, Saugstrup T, Santagostino E.	Haemophilia	2015	21	5	e436-9	doi: 10.1111/hae.12737.	Letter
52	Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.	Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, Jacobs I, Wuerfel T, Santagostino E.	Haemophilia	2015	21	6	784-90	doi: 10.1111/hae.12721.	Article
53	The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.	Jiménez-Yuste V, Lejniece S, Klamroth R, Suzuki T, Santagostino E , Karim FA, Saugstrup T, Møss J.	Journal of Thrombosis and Haemostasis	2015	13	3	370-9	doi: 10.1111/jth.12816.	Article
54	Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.	Oldenburg J, Zimmermann R, Katsarou O, Theodossiadis G, Zanon E, Niemann B, Kellermann E, Lundin B; Cross-sectional MRI study investigators (Santagostino E)	Haemophilia	2015	21	2	171-9	doi: 10.1111/hae.12539.	Article (multicenter study)
55	Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.	Meijer K, Rauchensteiner S, Santagostino E , Platokouki H, Schutgens RE, Brunn M, Tueckmantel C, Valeri F, Schinco PC.	Haemophilia	2015	21	1	e19-25	doi: 10.1111/hae.12530.	Article
56	Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.	Santagostino E , Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, Kilinc Y, Amit Y, Amendola A, Solimeno LP, Saugstrup T, Matytsina I.	Haemophilia	2015	21	1	34-40	doi: 10.1111/hae.12518.	Article
57	Switching treatments in haemophilia: is there a risk of inhibitor development?	Santagostino E , Auerswald G, Benson G, Dolan G, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Remor E, Zupančič Šalek S.	European Journal of Haematology	2015	94	4	284-9	doi: 10.1111/ejh.12433.	Review
58	Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid.	Tedeschi A, Marzano AV, Lorini M, Balice Y, Cugno M.	Journal of the European Academy of Dermatology and Venereology	2015	29	4	813-7	doi: 10.1111/jdv.12464.	Article

59	Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.	Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators (Moia M).	Circulation-Cardiovascular Quality and Outcomes	2015	8	2 (Suppl 1)	S12-20	doi: 10.1161/CIRCOUTCOMES.114.001556.	Article (multicenter study)
60	IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA	Mancuso ME, Cannavò A	Clinical investigation	2015	5	3	321-35		Review
61	Central venous access device (CVAD) complications in hemophilia with inhibitors undergoing immune tolerance induction: lessons from the International Immune Tolerance Study.	Rodriguez V, Mancuso ME , Warad D, Hay CR, DiMichele DM, Valentino L, Kenet G, Kulkarni R	Haemophilia	2015	21	5	e369-74	doi: 10.1111/hae.12740	Article
62	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.	Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A; AICE Working Group (Mancuso ME)	Blood Transfusion	2015	13	3	498-513	doi: 10.2450/2015.0141-1	Article (multicenter study)
63	Effects on health of air pollution: a narrative review.	Mannucci PM, Harari S, Martinelli I , Franchini M.	Internal and Emergency Medicine	2015	10	6	657-62	DOI 10.1007/s11739-015-1276-7	Review
64	Hypercoagulability is a stronger risk factor for ischemic stroke than for myocardial infarction: a systematic review	Maino A , Siegerink B, Algra A, Peyvandi F , Rosendaal FR	Plos One	2015	10	8	e0133523	doi: 10.1371/journal.pone.0133523	Article
65	Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women.	Siegerink B, Maino A , Algra A, Rosendaal FR	Journal of Thrombosis and Haemostasis	2015	13	9	1568-75	doi: 10.1111/jth.13045	Article
66	Evaluation of an heterogeneous group of VWD patients using an alternative assay to ristocetin induced platelet agglutination	Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F	Journal of Thrombosis and Haemostasis	2015	13	10	1806-14	doi: 10.1111/jth.13062	Article
67	Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy: comment.	Tripodi A, Chantarangkul V , Primignani M	Journal of Thrombosis and Haemostasis	2015	13	10	1941-3	doi: 10.1111/jth.13056	Letter
68	ASSOCIATION BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VENOUS THROMBOEMBOLISM	Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, Martinelli I	Thrombosis Research	2015	136	3	590-4	doi: 10.1016/j.thromres.2015.07.020	Article
69	Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia.	Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E , Pravettoni G.	Clinical Interventions in Aging	2015	10		1141-6	doi: 10.2147/CIA.S8474	Article

70	Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study.	Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F , Jalali A, Davaripasand T, Shahmansouri N, Lotfi-Tokaldany M, Abchouyeh MA, Isfahani FA, Rosendaal F	The Journal of Tehran University Heart Center	2015	10	1	34-42		Article
71	LONG TERM CLINICAL OUTCOMES OF SPLANCHNIC VEIN THROMBOSIS: RESULTS OF AN INTERNATIONAL REGISTRY	Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Mee Bang S, Senzolo M, Grandone E, Pasca S, Di Minno MND, Duce R, Malato A, Santoro R, Poli D, Verhamme P, Martinelli I , Kamphuisen P, Oh D, D'Amico E, Becattini C, De Stefano V, Vidili G, Vaccarino A, Nardo B, Di Nisio M, Dentali F. (+Appendix)	JAMA Internal Medicine	2015	175	9	1474-80	doi:10.1001/jamainternmed.2015.3184.	Article (multicenter study)
72	Current challenges and controversies in the management of chronic spontaneous urticaria	Asero R, Pinter E, Marra AM, Tedeschi A, Cugno M , Marzano AV.	Expert Review of Clinical Immunology	2015	11	10	1073-82	doi:10.1586/1744666X.2015.1069708	Review
73	Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.	Epcacan S*, Menegatti M* , Akbayram S, Cairo A , Peyvandi F , Oner AF	European Journal of Clinical Investigation	2015	45	10	1087-91	DOI: 10.1111/eci.12511	Article
74	Inhibitor development in non-severe haemophilia across Europe.	Fischer K, Iorio A, Lassila R, Peyvandi F , Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS participants (Mancuso ME)	Thrombosis and Haemostasis	2015	114	4	670-5	dx.doi.org/10.1160/TH14-12-1044	Article (multicenter study)
75	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.	Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F , Underwood M , Remuzzi G, Noris M	Clinical Journal of the American Society of Nephrology	2015	10	11	2002-12	doi: 10.2215/CJN.01700215	Article
76	Assesment of fibrinolysis in sepsis patients with urokinase modified thromboelastography	Panigada M, Zacchetti L, L'Acqua C, Cressoni M, Boscolo Anzoletti M , Bader R , Protti A, Consonni D, D'Angelo A, Gattinoni L	PLoS One	2015	10	8	e0136463	e0136463.doi:10.1371/journal.pone.0136463	Article
77	Pustular skin reaction to tumor necrosis factor alpha antagonists in patients with inflammatory bowel diseases.	Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M .	Inflammatory Bowel Diseases	2015	21	11	E26-7	doi: 10.1097/MIB.0000000000000600	Letter

78	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: laboratory weapons and their impact on treatment choice and monitoring.	Mannucci PM, Cugno M.	Thrombosis Research	2015	136	5	851-4	doi: 10.1016/j.thromres.2015.09.007	Article
79	The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.	Tripodi A , Legnani C, Palareti G.	Journal of Thrombosis and Haemostasis	2015	13	12	2283-6	doi: 10.1111/jth.13151.	Letter
80	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.	Matino D, Gargaro M, Santagostino E , Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME , Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F.	Journal of Clinical Investigation	2015	125	10	3766-81	doi: 10.1172/JCI81859	Article
81	International databases open the door to improved care for rare bleeding disorders	Peyvandi F	The Journal of Haemophilia Practice	2015	2	2	11-2	doi: 10.17225/jhp00051	Article
82	Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.	Bodó I , Eikenboom J, Montgomery R , Patzke J , Schneppenheim R , Di Paola J ; Subcommittee on von Willebrand factor (Baronciani L , Budde U, Castaman G, Federici AB, Friedman KD, Lawrie A, Peyvandi F , Sadler J, Haberichter S, Hampshire D, James P, Kokame K, Strebel J, Leebeek F, Tosetto A)	Journal of Thrombosis and Haemostasis	2015	13	7	1345-50	DOI: 10.1111/jth.12964	Article

83	Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH.	Hubbard AR, Heath AB, Kremer Hovinga JA; Subcommittee on von Willebrand Factor (Caron C, Eikenboom H, Maitzen S, Blum M, Eckmann C, Rentenaar J, Haberichter S, Kremer Hovinga J, Owen J, Neelamegham S, Fujimura Y, Falter T, Mirabet M, Kato S, Diaz-Ricart M, Mackie I, Bonnefoy A, Meijers J, Lombardi A, Sadler J, Muia J, Kimchi-Sarfaty C, Enjeti A, Chapman K, Baker R, Hubbard A, Daniels S, Veyradier A, Voisin S, Grandone E, Tiscia G, Budde U, Turecek P, Rottensteiner H, Peyvandi F, Valsecchi C , Binder N, Kitchen S, Fretwell R, Nair S, Vanhoorelbeke K.)	Journal of Thrombosis and Haemostasis	2015	13	6	1151-3	DOI: 10.1111/jth.12881	Article
84	Assessment of Clotting Factor Concentrates-Pivotal Studies and Long-Term Requirements	van den Berg HM, Peyvandi F .	Seminars in Thrombosis and Hemostasis	2015	41	8	855-9	dx.doi.org/10.1055/s-0035-1564799. ISSN 0094-6176.	Article
85	Gender difference in drug use in hospitalized elderly patients.	Santalucia P, Franchi C, Djade CD, Tettamanti M, Pasina L, Corrao S, Salerno F, Marengoni A, Marcucci M, Nobili A, Mannucci PM; REPOSI Investigators (Peyvandi F, Rossio R, Moreo G, Ferrari B)	European Journal of Internal Medicine	2015	26	7	483-90	doi: 10.1016/j.ejim.2015.07.006.	Article (multicenter study)
86	Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards.	Bellelli G, Nobili A, Annoni G, Morandi A, Djade CD, Meagher DJ, Maclullich AM, Davis D, Mazzone A, Tettamanti M, Mannucci PM; REPOSI (REgistro POliteratep SIMI) Investigators (Peyvandi F, Rossio R, Moreo G, Ferrari B)	European Journal of Internal Medicine	2015	26	9	696-704	pii: S0953-6205(15)00253-8.	Article (multicenter study)
87	VENOUS THROMBOSIS RISK AFTER CAST IMMOBILIZATION OF THE LOWER EXTREMITY: DERIVATION AND VALIDATION OF A CLINICAL PREDICTION SCORE (L-TRIP(CAST)) IN THREE POPULATION-BASED CASE-CONTROL STUDIES	Nemeth B, Adrichem RA, Hylckama Vlieg AV, Bucciarelli P, Martinelli I , Baglin T, Rosendaal FR, Cessie SI, Cannegieter SC.	PLoS Med	2015	12	11	e1001899	doi:10.1371/journal.pmed.1001899. eCollection 2015 Nov.	Article

88	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.	Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knoke K; adept™2 Investigators; adept 2 Investigators (Santagostino E)	Journal of Thrombosis and Haemostasis	2015	13	11	1989-98.	doi: 10.1111/jth.13141.	Article (multicenter study)
89	The Impact of Orthopaedic Surgery on The Quality of Life of Haemophilia Patients With or Without Inhibitors: A Systematic Review of The Literature.	Solimeno LP, Santagostino E , Giangrande PL, Damera V, Cure S, Slothuus U, Rosu GN, Wilkinson L	Value in Health	2015	18	7	A673	doi: 10.1016/j.jval.2015.09.1984	Article
90	Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases.	Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M.	Medicine (Baltimore)	2015	94	45	e1818	doi: 10.1097/MD.0000000000001818.	Article
91	Cytokine and Chemokine Profile in Amicrobial Pustulosis of the Folds: Evidence for Autoinflammation.	Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M.	Medicine (Baltimore)	2015	94	50	e2301	doi: 10.1097/MD.0000000000002301.	Article
92	Optimising musculoskeletal care for patients with haemophilia.	Carcao M, Hilliard P, Escobar MA, Solimeno L, Mahlangu J, Santagostino E.	European Journal of Haematology	2015	95	Suppl 81	11-21	doi: 10.1111/ejh.12581	Review
93	Rationale for individualizing haemophilia care	Sørensen B, Auerswald G, Benson G, Elezović I, Felder M, Lambert T, Morfini M, Remor E, Salaj P, Santagostino E , Šalek SZ, Ljung R.	BLOOD COAGULATION & FIBRINOLYSIS	2015	26	8	849-857	10.1097/MBC.0000000000000225	Review
94	Validity of the Modified Charlson Comorbidity Index as Predictor of Short-term Outcome in Older Stroke Patients	Denti L, Artoni A, Casella M2, Giambanco F, Scoditti U, Ceda GP.	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES	2015	24	2	330 - 336	10.1016/j.jstrokecerebrovasdis.2014.08.034.	Article